Meningitis - Pipeline Review, H1 2017

  • ID: 4318710
  • Report
  • 54 pages
  • Global Markets Direct
1 of 5
Meningitis - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Meningitis - Pipeline Review, H1 2017, provides an overview of the Meningitis (Infectious Disease) pipeline landscape.

Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life threatening.Viral meningitis is not life-threatening and the people affected with this can be cured and recover quickly, but bacterial meningitis is serious and life-threatening. There are three major bacteria which lead to bacterial meningitis. Neisseria meningitides are one of these, and causes meningococcal meningitis. Researchers have identified 13 major serogroups of N. meningitides, out of which the majority of cases are from one of five serogroups: A, B, C, Y and W-135. Drugs and vaccines are available to treat the serogroups AC, C, ACWY, and A. There are also vaccines available to prevent meningitis caused by serogroups A, C, Y, W-135. There are no vaccines or drugs available for the prevention and treatment of meningococcal meningitis caused by serogroup B. This represents a major unmet need in the market. Pneumococcal meningitis is another major bacterial cause of meningitis, caused by the bacteria streptococcus pneumonia, while haemophilius influenza is the third, and causes meningitis in infants. Approximatiely 44-46% cases of bacterial meningitis have all of the following three symptoms - severe headache, nuchal ridgidity ((inability to flex the neck forward passively due to increased neck muscle tone and stiffness) and altered mental status. Out of this triad of symptoms severe headache is the most common and occurs in 90% of the cases. If nove of the above mentioned symptoms are present, then occurrence of bacterial meningitis is least likely.Other clinical feature include photophobia (fear of bright light), phonophobia (fear of loud noises). In small children above symptoms are difficult to spot. Vague symptoms like irritability and unwell appearance are more common in them. In infants up to 6 months bulging of the fontanelle (soft spot on baby’s head) may be visible. Other less severe illnesses like extreme cold, abnormality in skin color and leg pain may also be distinguishing features for meningitis.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Meningitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Meningitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meningitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 3, 3 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Meningitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Meningitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Meningitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Meningitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Meningitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Meningitis (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Meningitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Meningitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
  1. Introduction
  2. Meningitis - Overview
  3. Meningitis - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Meningitis - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Meningitis - Companies Involved in Therapeutics Development
  15. Chongqing Zhifei Biological Products Co Ltd
  16. ContraFect Corp
  17. Matinas BioPharma Holdings Inc
  18. Viamet Pharmaceuticals Inc
  19. Meningitis - Drug Profiles
  20. (Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
  21. Product Description
  22. Mechanism Of Action
  23. R&D Progress
  24. amphotericin B - Drug Profile
  25. Product Description
  26. Mechanism Of Action
  27. R&D Progress
  28. CF-301 - Drug Profile
  29. Product Description
  30. Mechanism Of Action
  31. R&D Progress
  32. CF-302 - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. CF-303 - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. CF-305 - Drug Profile
  41. Product Description
  42. Mechanism Of Action
  43. R&D Progress
  44. CF-309 - Drug Profile
  45. Product Description
  46. Mechanism Of Action
  47. R&D Progress
  48. EUC-004 - Drug Profile
  49. Product Description
  50. Mechanism Of Action
  51. R&D Progress
  52. meningitis vaccine - Drug Profile
  53. Product Description
  54. Mechanism Of Action
  55. R&D Progress
  56. meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile
  57. Product Description
  58. Mechanism Of Action
  59. R&D Progress
  60. meningococcal [serotypes A, C] vaccine - Drug Profile
  61. Product Description
  62. Mechanism Of Action
  63. R&D Progress
  64. pneumococcal [serotype 4, 6A] vaccine - Drug Profile
  65. Product Description
  66. Mechanism Of Action
  67. R&D Progress
  68. Small Molecules to Inhibit Neuraminidase A for Infectious Diseases - Drug Profile
  69. Product Description
  70. Mechanism Of Action
  71. R&D Progress
  72. Vaccine to Target PknD for Tuberculous Meningitis - Drug Profile
  73. Product Description
  74. Mechanism Of Action
  75. R&D Progress
  76. VT-1129 - Drug Profile
  77. Product Description
  78. Mechanism Of Action
  79. R&D Progress
  80. VY-OZ - Drug Profile
  81. Product Description
  82. Mechanism Of Action
  83. R&D Progress
  84. Meningitis - Dormant Projects
  85. Meningitis - Discontinued Products
  86. Meningitis - Product Development Milestones
  87. Featured News & Press Releases
  88. Jun 02, 2017: Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis
  89. May 30, 2017: Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology's ASM Microbe 2017 Conference
  90. Jun 16, 2016: Clinical Trial of Phase III of Group A and Group C Meningococcal Conjugate vaccine Phase III Clinical Trial Initiated
  91. Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis
  92. Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis
  93. Jun 29, 2015: Olymvax obtains Chinese approval for clinical trials of Meningococcal conjugate vaccine
  94. Apr 24, 2015: Viamet to Provide Update on VT-1129, Novel Antifungal Program at ECCMID
  95. Sep 11, 2014: Viamet Receives Orphan Drug Designation for VT-1129
  96. Appendix
  97. Methodology
  98. Coverage
  99. Secondary Research
  100. Primary Research
  101. Expert Panel Validation
  102. Contact Us
  103. Disclaimer
List of Tables
  1. Number of Products under Development for Meningitis, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Products under Development by Companies, H1
  5. Products under Development by Universities/Institutes, H1
  6. Number of Products by Stage and Target, H1
  7. Number of Products by Stage and Mechanism of Action, H1
  8. Number of Products by Stage and Route of Administration, H1
  9. Number of Products by Stage and Molecule Type, H1
  10. Meningitis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1
  11. Meningitis - Pipeline by ContraFect Corp, H1
  12. Meningitis - Pipeline by Matinas BioPharma Holdings Inc, H1
  13. Meningitis - Pipeline by Viamet Pharmaceuticals Inc, H1
  14. Meningitis - Dormant Projects, H1
  15. Meningitis - Discontinued Products, H1
List of Figures
  1. Number of Products under Development for Meningitis, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Targets, H1
  4. Number of Products by Stage and Targets, H1
  5. Number of Products by Mechanism of Actions, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Routes of Administration, H1
  8. Number of Products by Stage and Routes of Administration, H1
  9. Number of Products by Molecule Types, H1
  10. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Chongqing Zhifei Biological Products Co Ltd
  • ContraFect Corp
  • Matinas BioPharma Holdings Inc
  • Viamet Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll